Philips shares the latest on HOT-HMV therapy

A Philips-sponsored study indicates that the combination of non-invasive ventilation (NIV) and home oxygen therapy (HOT) can significantly prolong time to readmission or death for patients with chronic obstructive pulmonary disease (COPD) and chronic hypercapnia following a life-threatening respiratory event or exacerbation. The five-year, multi-center study of 116 patient in the UK resulted in prolonged median time to readmission or death by nearly three months, and improved patient health-related quality of life in the first six weeks.

The results showed that the addition of home NIV to home oxygen therapy prolonged the median time to re-admission from 1.4 months to 4.3 months,¹demonstrating a breakthrough for COPD treatment.

The potential health economic impact within the US was previously unknown. However, the current study reports the incremental cost-effectiveness of HOT-HMV in patients with hypercapnic COPD.²The original trial data were used to develop an economic model, and findings were featured at the 2018 ATS International Conference in an abstract poster presentation from the payer perspective for both the U.S. and the UK.

The base-case incremental cost/QALY (quality adjusted life year) gained was negative $50,856,suggesting HOT-HMV as a dominant strategy (less expensive and more effective). Costs for HOT-HMV patients were $4,298 for devices, $10,805 for doctor visits, $758 for medication and $8,598 for exacerbations. HOT alone had the following costs: $1,582 for devices, $15,033 for doctor visits, $1,088 for medication and $10,683 for exacerbations.

In addition to the clinical effectiveness of HOT-HMV as previously reported, this data support cost effectiveness as well.

Looking for Philips ventilation and oxygen products?

Download 2018 product catalog

Put your team on the cutting edge of care

Take the inside track

Find out how at COPD Insider

Contact information

* This field is mandatory

Country

First name*

First name (phonetic)

Last name*

Last name (phonetic)

Salutation

Academic title

Email address*

Business phone

Company*

Job title

Industry

Function

Specialty

Department

State or Province

City

Address

Zip or Postal Code

By specifying your reason for contact we will be able to provide you with a better service.

Follow up information

Preferred method of contact

Best time to call

Estimated time of purchase

Comments

What is cross border data transfer?

I agree on cross-border transfer of personal information.

I would like to receive marketing related electronic communications about Philips products, services, events and promotions that may be relevant to me based on my user preferences and behavior.

ATS International Conference 2018 Abstract Poster

Cost-Effectiveness of Home Oxygen Therapy-Home Mechanical Ventilation (HOT-HMV) for Treatment of Chronic Obstructive Pulmonary Disease (COPD) with Chronic Hypercapnic Respiratory Failure Following an Acute Exacerbation of COPD in the United States (US)

Read the US abstract

Cost-Effectiveness of Home Oxygen Therapy-Home Mechanical Ventilation (HOT-HMV) for the Treatment of Chronic Obstructive Pulmonary Disease (COPD) with Chronic Hypercapnic Respiratory Failure Following an Acute Exacerbation of COPD in the United Kingdom (UK)

Read the UK abstract

¹Murphy PB, et al. Effect of Home Noninvasive Ventilation With Oxygen Therapy vs Oxygen Therapy Alone on Hospital Readmission or Death After an Acute COPD Exacerbation A Randomized Clinical Trial. JAMA. Published online May 21, 2017. doi:10.1001/jama.2017.4451